PLANTATION, Fla.--(BUSINESS WIRE)--Oncology Analytics, Inc., a URAC-accredited, leading provider of innovative oncology management services, today announced it has secured a $7.5 million investment. BlueCross BlueShield Venture Partners led the investment round with participation from Sandbox Advantage Fund. The Company will use the investment to broaden new product development, acquire additional strategic relationships and hire new positions to rapidly accelerate growth.
Oncology Analytics’ (OA) proprietary system, used in conjunction with an expert team of board certified clinical oncology specialists, provides treating physicians with the real-time expertise needed to assure that patients receive the highest quality of care while eliminating unnecessary costs. The company enhances patient care by ensuring that treating providers have the necessary information to deliver the most efficacious, least toxic and most affordable treatments available to patients. This assures patients, physicians, and insurers that treatment choices deliver high quality care and optimal value.
OA has experienced rapid growth and nationwide success in providing chemotherapy decision support services and is expanding to address all aspects of cancer care, from screening and diagnosis, to genetic and specialized testing, optimizing chemotherapy and radiation therapy for each patient’s individual needs, and for end-of-life care.
“I am delighted about this partnership with BlueCross BlueShield Venture Partners and Sandbox," said Dr. Marc Fishman, Chief Executive Officer and founder of Oncology Analytics. "The additional resources and expertise will enable OA to continue to expand its services and assure that all patients receive the highest quality of medical care in oncology and in other fields of medicine.”
"We are thrilled to have the opportunity to work with Dr. Fishman and the rest of the Oncology Analytics team to help raise the standard of care for oncology patients across the country. The collaborative approach that Oncology Analytics takes has led to great results already. This is a space where everyone can win - patient, provider and payer," said Dr. Thomas Hawes, Managing Director of Sandbox Industries, who represents BlueCross BlueShield Venture Partners on the Board.
About Oncology Analytics, Inc.
Oncology Analytics, Inc. provides chemotherapy decision support services, clinical expertise, and physician-centric customer services. Dr. Marc Fishman founded OA in 2009 after more than 20 years of direct clinical care experience. OA’s web-based clinical decision support system consists of over 2,800 treatment protocols. OA utilizes an expert team of in-house board certified hematologists and oncologists for peer review who are supported by a distinguished academic advisory board. Visit www.oncologyanalytics.com or call 888-916-2616 to learn more.
About BlueCross BlueShield Venture Partners
BlueCross BlueShield Venture Partners, L.P. is a corporate venture fund licensed by the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield companies. The fund invests in promising emerging companies of strategic relevance to Blue Cross and Blue Shield Plans. Sandbox Industries is the exclusive provider of investment management services to BlueCross BlueShield Venture Partners. For more information, please visit www.bcbsvp.com.
